Sec Form 3 Filing - Bios Clinical Opportunity Fund, LP @ ACTUATE THERAPEUTICS, INC.

Insider filing report for Changes in Beneficial Ownership

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Here is the list of insider trading transaction codes

FORM 3

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

November 30, 2011

Estimated average burden hours per response...

0.5

1. Name and Address of Reporting Person

Bios Clinical Opportunity Fund, LP

2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	X __ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O BIOS EQUITY PARTNERS 1751 RIVER RUN, SUITE 400

3. Date of Earliest Transaction (MM/DD/YY)
08/12/2024

(Street)

FORT WORTH, TX76107

4. If Amendment, Date Original Filed (MM/DD/YY)

6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								84,917	I	Directly held by BP Directors, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Common Stock								60,973	D
Common Stock								8,056	I	Directly held by KF Legacy Trust U/A/D December 7, 2016 ^{( 4 )}
Common Stock								8,056	I	Directly held by MF Legacy Trust U/A/D December 7, 2016 ^{( 4 )}
Common Stock								69,375	I	Directly held by Circle K Invesco, LP ^{( 5 )}

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
( *e.g.* , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Ex ercisable and Expiration Date (MM/DD/YY)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Convertible Note	^{( 6 )}							^{( 6 )}	^{( 6 )}	Common Stock	^{( 6 )}			I	Directly held by Bios Clinical Opportunity Fund, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series A Redeemable Convertible Preferred Stock	^{( 7 )}							^{( 7 )}	^{( 7 )}	Common Stock	525,797			I	Directly held by Bios Fund I, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series A Redeemable Convertible Preferred Stock	^{( 7 )}							^{( 7 )}	^{( 7 )}	Common Stock	307,538			I	Directly held by Bios Fund I QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-1 Redeemable Convertible Preferred Stock	^{( 8 )}							^{( 8 )}	^{( 8 )}	Common Stock	141,457			I	Directly held by Bios Fund II, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-1 Redeemable Convertible Preferred Stock	^{( 8 )}							^{( 8 )}	^{( 8 )}	Common Stock	462,073			I	Directly held by Bios Fund II QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-1 Redeemable Convertible Preferred Stock	^{( 8 )}							^{( 8 )}	^{( 8 )}	Common Stock	61,857			I	Directly held by Bios Fund II NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-1 Redeemable Convertible Preferred Stock	^{( 8 )}							^{( 8 )}	^{( 8 )}	Common Stock	153,702			I	Directly held by Bios Actuate Co-Invest I, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-2 Redeemable Convertible Preferred Stock	^{( 9 )}							^{( 9 )}	^{( 9 )}	Common Stock	54,032			I	Directly held by Bios Fund II, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-2 Redeemable Convertible Preferred Stock	^{( 9 )}							^{( 9 )}	^{( 9 )}	Common Stock	176,499			I	Directly held by Bios Fund II QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-2 Redeemable Convertible Preferred Stock	^{( 9 )}							^{( 9 )}	^{( 9 )}	Common Stock	23,628			I	Directly held by Bios Fund II NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-2 Redeemable Convertible Preferred Stock	^{( 9 )}							^{( 9 )}	^{( 9 )}	Common Stock	147,047			I	Directly held by Bios Actuate Co-Invest I, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-3 Redeemable Convertible Preferred Stock	^{( 10 )}							^{( 10 )}	^{( 10 )}	Common Stock	101,900			I	Directly held by Bios Fund II, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-3 Redeemable Convertible Preferred Stock	^{( 10 )}							^{( 10 )}	^{( 10 )}	Common Stock	332,867			I	Directly held by Bios Fund II QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-3 Redeemable Convertible Preferred Stock	^{( 10 )}							^{( 10 )}	^{( 10 )}	Common Stock	44,559			I	Directly held by Bios Fund II NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-4 Redeemable Convertible Preferred Stock	^{( 11 )}							^{( 11 )}	^{( 11 )}	Common Stock	309,589			I	Directly held by Bios Fund III, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-4 Redeemable Convertible Preferred Stock	^{( 11 )}							^{( 11 )}	^{( 11 )}	Common Stock	2,022,029			I	Directly held by Bios Fund III QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-4 Redeemable Convertible Preferred Stock	^{( 11 )}							^{( 11 )}	^{( 11 )}	Common Stock	326,547			I	Directly held by Bios Fund III NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B-4 Redeemable Convertible Preferred Stock	^{( 11 )}							^{( 11 )}	^{( 11 )}	Common Stock	2,094,650			I	Directly held by Bios Actuate Co-Invest II, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series C Redeemable Convertible Preferred Stock	^{( 12 )}							^{( 12 )}	^{( 12 )}	Common Stock	74,202			I	Directly held by Bios Fund III, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series C Redeemable Convertible Preferred Stock	^{( 12 )}							^{( 12 )}	^{( 12 )}	Common Stock	484,638			I	Directly held by Bios Fund III QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series C Redeemable Convertible Preferred Stock	^{( 12 )}							^{( 12 )}	^{( 12 )}	Common Stock	78,267			I	Directly held by Bios Fund III NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series C Redeemable Convertible Preferred Stock	^{( 12 )}							^{( 12 )}	^{( 12 )}	Common Stock	573,394			I	Directly held by Bios Actuate Co-Invest III, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B Warrant (Right to Buy)	$ 5.27							09/07/2018	^{( 13 )}	Common Stock	8,068			I	Directly held by Bios Fund II, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B Warrants (Right to Buy)	$ 5.27							09/07/2018	^{( 13 )}	Common Stock	26,355			I	Directly held by Bios Fund II QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B Warrants (Right to Buy)	$ 5.27							09/07/2018	^{( 13 )}	Common Stock	3,528			I	Directly held by Bios Fund II NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B Warrant (Right to Buy)	$ 10.54							09/07/2018	^{( 13 )}	Common Stock	8,068			I	Directly held by Bios Fund II, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B Warrants (Right to Buy)	$ 10.54							09/07/2018	^{( 13 )}	Common Stock	26,355			I	Directly held by Bios Fund II QP, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Series B Warrants (Right to Buy)	$ 10.54							09/07/2018	^{( 13 )}	Common Stock	3,528			I	Directly held by Bios Fund II NT, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}
Stock Options	$ 2.14							^{( 14 )}	04/29/2033	Common Stock	31,884			I	Directly held by BP Directors, LP ^{( 1 )} ^{( 2 )} ^{( 3 )}

**Reporting Owners**
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Bios Clinical Opportunity Fund, LP C/O BIOS EQUITY PARTNERS 1751 RIVER RUN SUITE 400 FORT WORTH, TX76107		X
Bios Equity COF, LP C/O BIOS EQUITY PARTNERS 1751 RIVER RUN SUITE 400 FORT WORTH, TX76107		X
BP Directors, LP C/O BIOS EQUITY PARTNERS 1751 RIVER RUN SUITE 400 FORT WORTH, TX76107		X

**Signatures**
Bios Clinical Opportunity Fund, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager		08/12/2024
Signature of Reporting Person		Date
Bios Equity COF, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager		08/12/2024
Signature of Reporting Person		Date
BP Directors, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager		08/12/2024
Signature of Reporting Person		Date

Explanation of Responses:

( 1 )Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III").
( 2 )Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF"). Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
( 3 )The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III and Bios COF (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
( 4 )Shares are held in a trust, which has an independent trustee, for the benefit of Mr. Fletcher's children. Mr. Fletcher disclaims beneficial ownership of such shares other than to the extent he may have a pecuniary interest therein.
( 5 )Shares are held by Circle K Invesco, LP, over which Mr. Kreis has sole voting and investment control.
( 6 )Reflects a convertible note that is convertible into shares of common stock of the Issuer. The convertible note has a maturity date of July 31, 2024. The principal amount of the convertible note together with accrued interest will be automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering ("IPO") at a conversion price equal to the initial offering price multiplied by 0.8.
( 7 )Each share of Series A Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock has no expiration date.
( 8 )Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock has no expiration date.
( 9 )Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock has no expiration date.
( 10 )Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock has no expiration date.
( 11 )Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock has no expiration date.
( 12 )Each share of Series C Redeemable Convertible Preferred Stock preferred stock will automatically convert into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock has no expiration date.
( 13 )The warrants are exercisable until the earliest to occur of (i) September 7, 2028, (ii) the consummation of a change in control of the Issuer and (iii) two years after the first closing of the Issuer's IPO. Upon the closing of the Issuer's IPO, each warrant shall automatically be exercised on a cashless basis if the exercise price is less than the initial public offering price.
( 14 )The options are fully vested.

Remarks:
This Form 3 is the third of three Forms 3 filed relating to the same event. The Form 3 has been split into three filings because there are more than 20 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 3 to a maximum of 10 reporting persons. The first Form 3 was filed by Leslie W. Kreis as the designated filer. The second Form 3 was filed by Aaron G.L. Fletcher as the designated filer. Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Sec Form 3 Filing - Bios Clinical Opportunity Fund, LP @ ACTUATE THERAPEUTICS, INC. - 2024-08-12